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The significance of this study is to determine the degree of
inconsistency in dosing practice of DOACs at a quaternary care
institution such as Thomas Jefferson University Hospital.
1. What is the primary indication for anticoagulation in
out population?
2. What percentage is dosed correctly?
3. Are patients primarily over or underdosed?
Retrospective Chart Review
Apixaban Rivaroxaban
Patients with chronic kidney disease on
a direct oral anticoagulant or warfarin
queried from 2017-2019 at TJUH
= 4,276 Patients
Primary focus was DOACs requiring renal
dosage adjustment (apixaban and
rivaroxaban). Screened >500 patients.
Excluded patients on warfarin, other
DOACs, and CKD 1-3a.
235 patients on either Apixaban or
Rivaroxaban with CKD 3b-5 or ESRD
59 patients chart reviewed168 patients chart reviewed






20mg daily (15mg if 
CrCl 15-50)
Apixaban (Eliquis)
5mg BID (2.5 mg if 
Cr≥1.5 AND age ≥ 80 




Age (mean (SD)) 68.74 (12.48) 72.80 (7.95) 0.021
Female (%) 81 (48.2) 26 (44.1) 0.691
Level of Kidney Injury (%) <0.001
CKD 3b 30 (17.9) 27 (45.8)
CKD 4 67 (39.9) 19 (32.2)
CKD 5 2 ( 1.2) 8 (13.6)
ESRD 69 (41.1) 5 ( 8.5)
Anticoagulation Indications
CDK 3-5 ESRD p-value
n 153 74
Atrial fibrillation/flutter (%) 115 (75.2) 44 (59.5) 0.023
DVT or PE (%) 35 (22.9) 27 (36.5) 0.046
Post Surgical (%) 0 ( 0.0) 1 ( 1.4) 0.710
Other (%) 3 ( 2.0) 1 ( 1.4) 1.000
Percent Dosed Correctly
58% 76% 47.8% 100% 65% 74%
Based on the data reviewed there is significant variability in
dosing of DOACs-primarily apixaban and rivaroxaban
• 42% of patients with severe chronic kidney disease or end-
stage renal disease were incorrectly dosed with apixaban
(p = 0.02) – overwhelmingly underdosed!
• More than half (53%) of patients on dialysis were incorrectly
dosed with apixaban (p = 0.07)!
• 35% of patients with severe chronic kidney disease were
dosed incorrectly with apixaban compared to 25% with
rivaroxaban.
Proposed Next Steps
1. Gauge interdisciplinary understanding on DOAC
dosing in renal impairment via survey
2. Discuss possible EPIC alerts or checklists when
dosing apixaban or rivaroxaban to avoid
underdosing
3. Analyze outcomes as a result of incorrect dosing
1. Limited power in severe chronic kidney disease arm –
will need to continue analyzing more patients in this
population to determine if statistically significant
difference exists, however preliminary data is quite
stark
2. Multiple chart reviewers with varying techniques
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